1. Introduction {#s0005}
===============

It is thought that recurrently mutated amino-acid positions in cancer genes, namely mutation hotspots, are likely to have an important functional impact [@b0005]. Several well-known examples support this view. One of the most frequent hotspots, BRAF V600E mutation, is known to over-activate the RAS pathway [@b0010], [@b0015]. BRAF is top mutated in thyroid carcinoma [@b0020], melanoma [@b0025], and hairy-cell leukemia [@b0015], and also frequent in colon and lung cancers [@b0030], [@b0035], [@b0040]. Other hotspots are also well-known such R132H in IDH1 for low-grade gliomas [@b0045], G12/G13 in KRAS for lung [@b0050], and Q61 in NRAS for melanoma [@b0055]. Many other genes also show hotspots [@b0060].

Some non-cancer genes seem to show hotspots that become clear when mutations from all cancers are aggregated [@b0005], [@b0060], [@b0065]. For example, in Chang *et al.* analysis [@b0065], the RRAS2 showed a hotspot in Q72, which is still not marked as a cancer gene in the Cosmic curated database revision 2019 [@b0070] neither detected for positive selection in Martincorena analysis [@b0075]. This suggests that the identification of putative novel hotspots is important in cancer.

Some methods have been reported regarding the detection of mutation hotspots. Of the seminal approaches, there was a tendency to identify regions [@b0080], [@b0085] or domains [@b0005], [@b0090] when the available mutations were more limited. Similarly, some approaches focused on the three-dimensional protein structure to identify mutation-rich 3D-regions [@b0095], [@b0100], [@b0105]. Then, position-specific models were proposed [@b0060], [@b0065], [@b0110], [@b0115]. These approaches used a binomial or a Poisson distribution to model mutation distribution across genes. Nevertheless, the mutation distribution per gene may depend on cofactors such as sequence context [@b0060], gene length [@b0120], cancer type [@b0125], [@b0130], mutational processes [@b0130], [@b0135], or relative position along nucleosomes [@b0140]. Modeling all these cofactors together is a very difficult task given its complexity and lack of data to sufficiently estimate embed parameters. To account for these and other unknown factors, an over-dispersion model is preferred [@b0075], [@b0120], [@b0145]. Thus, other approaches utilize more appropriate models such as the beta-binomial model [@b0120], [@b0145], which were applied to non-coding regions.

Although the above methods have been useful, there are some pitfalls. Some approaches use binomial or Poisson models with one or two cofactors [@b0060], [@b0065], [@b0110] but this may lead to many unconvinced predictions. For example, there are 20 genes reported by Chang *et al.* [@b0065] that show significant "hotspot" associations where the "hotspots" are supported by two mutations only (e.g. SESN2 in [[https://www.cancerhotspots.org/]{.ul}](https://www.cancerhotspots.org/){#ir015}), which still seems biologically weak for validation purposes. Pursuing experimental validations on SENS2 would be very difficult if there is no available information about the parameters fitted and all related information used regarding the gene and mutations. Some methods use randomization of the mutations to estimate significance [@b0005] but this would lead to biased estimations if not all cofactors are considered, which is difficult because there is still uncertainty about possible cofactors. Other methods use well-known cancer genes as positive controls and presumed negatives to estimate sensitivity and specificity [@b0150]. One of the reported problems of this strategy is that it sacrifices sensitivity for specificity [@b0150], which may show difficulties when used as a discovery tool. In this context, simulations may be a good strategy.

One of the strengths of methods that detect regions, domains, and 3D structures is that estimations can be more reliable because many more mutations can be analyzed within regions than within positions. Nevertheless, this is also a weakness because it is known that the sequence context plays a role [@b0060] and these methods lack nucleotide sequence resolution. Another issue is that some methods focus on single nucleotide variants, presumably because of the lack of corrections for small insertions and deletions (INDELS) [@b0065]. Regarding the types of mutations, most referred methods focus mainly on missense mutations. This is sensible because these hotspots mark positions on the protein that may change its function. Besides, missense mutations represent a large proportion of all mutations. Nevertheless, other mutations may be interesting such as those generated by small insertions and deletions that may easily accumulate at repetitive sequences [@b0155]. A deeper analysis of methods is presented elsewhere [@b0160].

In this work, firstly, a comparison of the fitting of the distribution of all types of small mutations by two canonical distributions (*Binomial, Geometric*) and two more that consider over-dispersion (*Beta-Binomial,* and *Zero-Inflated Beta-Binomial*) is presented. The comparison leads to the determination that, overall, the *beta-binomial* model seems to be the best model. Then, to account for genuine hotspots that do not fit well even considering over-dispersion by the b*eta-binomial*, a mixture model with fixed effects is proposed to better fit the observed mutation distribution per gene without covariates. The need of fixed effects on high frequent mutations suggests the presence of hotspots. Simulations show that the proposed mixture model is accurate. Then, the mixture model has been applied to *The Cancer Genome Atlas* (TCGA) dataset and the putative hotspots are analyzed. The analysis shows that there is a bias for a sequence context centered at the mutation position and that systematic bias is observed in most co-localized olfactory receptors and other co-localized gene families. More importantly, some detected genes not considered as mutations hotspots show comparable statistics that current well-known cancer genes carrying hotspots. To the author knowledge, this is one of the few methods that use simulations to evaluate the sensitivity and specificity of the proposed method.

2. Material and methods {#s0010}
=======================

2.1. Mutational data {#s0015}
--------------------

The mutation annotation files (maf) were obtained from the public cancer repository TCGA ([[http://firebrowse.org/]{.ul}](http://firebrowse.org/){#ir020}) in January 2018 corresponding to 33 cancer types, 10,182 patients, and 3,175,929 mutations ([Supplementary Table 1](#s0110){ref-type="sec"}). Only mutations annotated to an amino acid position within its corresponding transcript were used.

2.2. Distribution of mutated positions {#s0020}
--------------------------------------

For each gene, the mutations were counted per amino acid position depending on their corresponding transcript and protein. Then, the number of amino acid positions having *m~g,i~* mutations (from *0* to *M~g~*) were aggregated where *g* is the gene, *i* is the number of mutations, and *M~g~* is the maximal number of mutations of gene *g* at any amino acid position.

2.3. Distribution models {#s0025}
------------------------

To find the optimal parameters to fit a distribution model to the histogram of mutational data, a numerical method implemented in the *optim* function from the *stat* package was used minimizing the difference to the observed distribution (method="L-BFGS-B" for function *optim* in *stats* package in R, [[https://cran.r-project.org/]{.ul}](https://cran.r-project.org/){#ir025}). To estimate the difference between fitted and observed distribution was based on the *G-test* statistic, $G = 2\sum o_{i}log\left( {o_{i}/e_{i}} \right)$, which is equivalent to the Kullback--Leibler divergency metric used to compare distributions. The geometric and binomial distributions were fitted using the *stat* package in R. The Zero-inflated beta-binomial (ZIBB) was fitted using the *gamlss* package in R. The beta-binomial was fitted using the *emdbook* package in R.

2.4. Beta-binomial model with fixed effects {#s0030}
-------------------------------------------

Conceptually, the problem is schematized in [Fig. 1](#f0005){ref-type="fig"}A while the algorithm is shown in [Fig. 1](#f0005){ref-type="fig"}B. The model, $M = BetaBin\left( {\alpha,\beta} \right) + F$, assumes a fixed effect on positions with an excess of mutations presumably due to hotspots where *M~k~* is the number of positions carrying *k* mutations, *F* is the fixed hotspot effect vector, and *BetaBin* is the beta-binomial density function scaled conveniently to sum the total number of mutations minus the sum of *F*. A step-wise algorithm was devised to fit this model. The algorithm starts setting *F~k~ = 0* and fitting the *beta-binomial* model using an optimization algorithm as described in previous section. Then, a matrix of improvements is estimated where each cell represents an independent possible fixed effect in a mutation number *k* (in columns) and at a fraction of the total number of sites (in rows). The value of the cell is a ratio of improvement equal to the *G* statistic before applying the fixed effect divided by the *G* statistic after applying the representing fixed effect. The largest ratio represents an improvement if higher than 1 and therefore it is taken. The corresponding level (positions) and number of mutations *f~i,k~* are aggregated to the *F* vector of fixed effects. The algorithm continues until the largest ratio is not greater than 1 (no improvement), when the number of steps is larger than 2 times the maximum number of mutations, or when the *G* statistic is lower than 1 to avoid over-fitting. To improve speed, the 0 positions (*k = 0*), the zero mutations (*m~g,i~ = 0*), fractions that do not achieve at least 1 mutation in any *k* mutations, or fractions representing mutations already calculated, are not explored. The output of the algorithm is the fixed effect vector *F* representing the mutations and the magnitude (number of positions), *F~k~*, that cannot be explained by the *beta-binomial* model, and the updated parameters α, and β. The algorithm was implemented in R and is available upon request.Fig. 1**Hotspot concept and proposed algorithm.** (A) Cartoon conceptualization of random mutations along a protein (top) and similar number of mutations resulting in two hotspots (bottom). Histogram of positions per number of mutations. The fit of a Beta-binomial model is shown as blue dashed line. Count are missing for clarity. (B) Proposed algorithm to find the optimal α, β, and *F* parameters of the mixed model that better fit the observed mutation distribution. In each iteration (*i*), *[F~k~]{.ul}*, the *k* component of F, is updated from the best improvement, if any. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

2.5. Simulations {#s0035}
----------------

For simulations, the parameters α and β were taken from the observed distributions of the fitted beta-binomial models obtained for cancer data. Then the *F* vector was added depending on the simulation. For no hotspots, *F~k~ = 0*, otherwise some *F~k~ \> 0*. In any case, after running the proposed algorithm, if the fitted value of *F~k~* is larger than 50% of the mutations at *k,* the residue positions having *k* mutations were recognized as hotspots. From the 2,000 genes taken for simulations, only 1,973 genes generated successful distributions.

2.6. Hotspots from cancer data {#s0040}
------------------------------

For cancer data, a hotspot or biased position was recognized if the fitted value of *F~k~* is larger than 50% of the mutations, whose mutations were 4 or more, and whose q-value (corrected p-value) was ≤0.01. These criteria were used to avoid calling hotspots at positions of low number of mutations (e.g., mutations \< 4) that helped to improve model fitting but unlikely to represent hotspots (see [Supplementary Fig. 1](#s0110){ref-type="sec"}).

2.7. Sequence context {#s0045}
---------------------

The context sequence of a mutation was annotated using the R package *BSgenome.Hsapiens.NCBI.GRCh38*.

3. Results {#s0050}
==========

3.1. Comparisons of competing distributions {#s0055}
-------------------------------------------

To determine the best canonical distribution matching the observed mutations distributions in cancer, a comparison was performed between binomial, geometric, beta-binomial, and zero-inflated beta-binomial (ZIBB) [@b0165]. For this, the Kullback-Leiber divergency metric was used to determine which distribution provides the best fit to the observed distribution. The ZIBB was included due to the observation that sites at zero mutations seem to be exacerbated. Under randomness, the binomial is the expected result. Nevertheless, the results show that the *beta-binomial* and the *geometric* functions capture the largest number of genes ([Supplementary Fig. 2A](#s0110){ref-type="sec"}). The former is expected because the beta-binomial can capture over-dispersion commonly present in binomial data [@b0170]. However, the *geometric* distribution performed surprisingly high. Then, to assess whether there is a preference of a density function for cancer genes, the same process was performed for cancer genes according to Cosmic [@b0070] or Martincorena [@b0075] and, on the other hand, for olfactory factors, which are believed to be mostly negative for cancer genes [@b0175]. The results demonstrate that the *beta-binomial* and the *geometric* distributions dominates the best fit ([Supplementary Fig. 2A](#s0110){ref-type="sec"}). If only the *beta-binomial* and the *geometric* distributions were compared, 63% of the genes were best fitted using the *beta-binomial* ([Supplementary Fig. 2B](#s0110){ref-type="sec"}). Moreover, for those genes best fitted with the *geometric* distribution, 98% would best fit the *beta-binomial* if the *geometric* were not considered whereas the genes best fitted with *beta-binomial* would not prefer the *geometric* ([Supplementary Fig. 2C](#s0110){ref-type="sec"}). These results suggest that, overall, the best distribution tested is the *beta-binomial*.

3.2. Hotspot detection algorithm {#s0060}
--------------------------------

As shown above, the *beta-binomial* distribution seems to be a good model for most of the genes and it has been used to estimate recurrent alterations [@b0180], [@b0185], [@b0190]. The use of a distribution is interesting because it provides the probability of observing *k* mutations allowing the possibility of assigning a p-value to biased amino acid positions (putative hotspots). Although a distribution could be a good model, the presence of hotspot mutations or biased sites would artificially increase the mutations counts at specific positions generating longer tails. This will generate deviations in the parameter values modifying the corresponding p-values and therefore falsely calling or not calling hotspots at uncertain conditions. To handle this, a mixed model is proposed having two components as $M = BetaBin\left( {\alpha,\beta} \right) + F$ where *M~k~* is the count of amino acid positions mutated *k* times. Without hotspots or deviated sites, the *F* vector is zero (all *F~k~ = 0*) and the number of amino acid sites mutated are explained entirely by the *beta-binomial* component. This would generate very low differences between the observed and fitted distribution, which is measured by the Kullback-Leiber (KL) divergency (or *G-test*, see Methods). In the presence of hotspots or sequence biases, the KL divergency will be higher. Nevertheless, within the model, *F* can absorb the excess of amino acid positions at *k* mutations (*F~k~ \> 0)*, providing a better fit for the *beta-binomial* and lowering the KL divergency. Therefore, the problem is to find the optimal values of *α*, *β*, and *F*. For this, the devised stepwise algorithm, schematized in [Fig. 1](#f0005){ref-type="fig"}B, first sets *F~k~ = 0*, then finds the most deviated amino acid positions at *k* mutations looking for lower values of cell scores. This is achieved exploring the possible combinations of *k* mutations and fractions of amino acid positions. In the example shown in [Fig. 1](#f0005){ref-type="fig"}B, the first iteration finds *F~7~ = 1* while the second iteration finds *F~6~ = 1*. The process ends because there is no sufficient improvement at the third iteration. In this way, the fitted *beta-binomial*, conditioned to the fitted *F,* is more representative of most sites and mutations providing an unbiased estimation of the probability of *k* mutations at updated parameters *α* and *β*, which can be very different to those parameters without using the fixed effect at the start of the algorithm. Indeed, the differences are clear in both parameters for cancer data ([Supplementary Fig. 3A-B](#s0110){ref-type="sec"}). The convergence of the algorithm was relatively fast ([Supplementary Fig. 3C-D](#s0110){ref-type="sec"}). Only 13 genes needed more than 10 iterations.

3.3. Assessing the performance of the proposed algorithm {#s0065}
--------------------------------------------------------

To objectively evaluate the performance of the proposed algorithm, simulations were used. The first simulation was performed assuming no hotspots. To simulate realistic scenarios, all genes were first fit to the *beta-binomial* without a fixed effect*.* Then, the observed *α~g~*, and *β~g~* values for 2,000 random genes *g* were used to generate positions distributions at the same number of the observed mutations. Finally, the proposed algorithm was run with this artificial data. The results show that the proposed algorithm has a specificity of 84.3% recognizing 0 hotspots when there are none ([Fig. 2](#f0010){ref-type="fig"}A).Fig. 2**Performance of the proposed algorithm on simulated data.** (A) Distribution of the number of detected hotspots in simulation 1, which does not inject hotspots. (B) Injection of *nHot* hotspots in position *rMut*, relative to the maximum number of mutations (4 in the example shown). The left histogram shows initial data. The middle and right histogram show the result of adding 2 or 1 hotspots carrying 3 or 5 mutations respectively where *rMut = −1* refers to 1 mutation less than 4 (at 3 mutations), while *rMut = +1* refers to 1 mutation greater than 4 (at 5 mutations). Finally, the *nHot* is the number of amino acid positions added to the specified number of mutations. (C) Overall results of all simulations having hotspots. Here 'detected hotspot' stand for the sum of *F~k~* values \> 0 from fitted *F* vectors. (D) shows the performance of the algorithm depending on *rMut* and *nHot*. Each combination shows the percentage of simulated genes that showed the corresponding hotspots at the relative number of mutations (rounded for clarity, some cells may differ by 0.05).

The second simulation was performed assuming one or more hotspots (or biased amino acid positions). Note that the number of amino acid positions or the number of mutations is important because it could deviate far from the overall distribution or can be masked within dense regions of the distribution. For example, in [Fig. 1](#f0005){ref-type="fig"}A, there is one hotspot carrying 6 mutations and another carrying 7 mutations, which are at +3 and +4 mutations farther than the last mutated 'random' mutation at 4. Similarly, in [Fig. 2](#f0010){ref-type="fig"}B, two examples are shown. First, two hotspots are added having 3 mutations (relative to the maximum 4, these are at *rMut = −1*). Then one hotspot is added at 5 mutations (*rMut=+1)*. To generalize for any gene, for the simulations, the number of amino acid positions injected were *nHot={1, 3, 5}* whereas the number of mutations tested was *rMut={−3, −2, −1, 0, 1, 3, 5}* relative to the maximum number of observed mutations. In this way, injected hotspots at *rMut* ≤ *0* are harder to detect because are mixed with the overall distribution. Contrary, high values of *rMut* or larger *nHot* are easier to detect because the alteration has a deeper impact on the distribution. For these simulations, the same 2,000 genes employed in the first simulations were used. The results show that the proposed algorithm only fails to detect at least one hotspot in 15% of the simulations ([Fig. 2](#f0010){ref-type="fig"}C). Thus, the algorithm has an overall sensitivity of 85%. Nevertheless, in more than 10% of the simulations, more than one hotspot was detected. To study the conditions of this behavior deeply, the performance of the algorithm for different *rMut* values was analyzed as shown in [Fig. 2](#f0010){ref-type="fig"}D. The ideal well-known hotspots should contain more than the maximum random mutations, which corresponds to *rMut \> 0.* The performance in these ideal hotspots was ≥99% for 1, 3, and 5 injected hotspots. If the hotspots are precisely the ones at the maximum number of mutations (*rMut = 0*), the performance is 76% if there is only one hotspot, or close to 100% if there are 3 or more. If a hotspot is present but in the observed data is still below the maximum number of mutations (corresponding to *rMut \< 0*), the performance decreases with both *nHot*, and *rMut* ([Fig. 2](#f0010){ref-type="fig"}D). This scenario seems counterintuitive but because data in cancer has not been uniformly nor comprehensive acquired in all cancer types, it may be still useful if detected. In these cases, if only one hotspot is present, the overall performance decreases to 81%, 50%, or 21% corresponding to −1, −2, and −3 relative mutations and more than 15% of the times another false 'hotspot' is detected (see rows at *rMut = −1, −2, −3* and columns 2, 4, and 6). When three or five hotspots are present below the maximum mutations, the performance is in general higher but also increases the number of false 'hotspots' detected.

In summary, the proposed algorithm has an ideal performance (\>99% sensitivity and specificity) when the hotspots are those at the maximum number of mutations and the performance decreases with the number of hotspots or the relative position to the maximum number of mutations.

3.4. Detecting hotspots in cancer data {#s0070}
--------------------------------------

From the proposed algorithm, the fixed effects *F* absorbs those positions that cannot be explained by the *beta-binomial* model alone. Thus, the fixed effect vector *F* mark hotspots while the fitted *beta-binomial* is able to, less biasedly, estimate its probability. The p-value was then corrected by a false discovery rate (FDR) approach [@b0195]. Because potential hotspots are only those with a sensible number of recurrent positions, the FDR correction was estimated for sites whose recurrence were 4 or more. Only positions having FDR ≤ 0.01 were considered as hotspots. This was applied to TCGA mutational data, which includes 3,175,929 mutations from 10,182 patients across 33 cancer types ([Supplementary Table 1](#s0110){ref-type="sec"}). As a correction, hotspots were also called if the number of mutations were 9 or greater which includes many amino acid positions in *TP53*, *PIK3CA*, and *PTEN*, which result presumably to the overwhelming number of hotspots in these genes ([Supplementary Fig. 4](#s0110){ref-type="sec"}). The detected hotspots are part of a database, *Hotspots Annotations* [@b0200], available online ([[http://bioinformatica.mty.itesm.mx/HotSpotsAnnotations]{.ul}](http://bioinformatica.mty.itesm.mx/HotSpotsAnnotations){#ir030}). Some representative examples of the hotspot detection are shown in [Fig. 3](#f0015){ref-type="fig"}. For a well-known cancer gene, *EGFR*, 4 hotspots are clearly recognized carrying from 11 to 27 mutations. In addition, there were 4 AA positions carrying 5 mutations, 1 of 6 mutations, and 2 of 7 mutations that were effectively recognized by the algorithm but that were not significant under the above criteria after FDR correction. Similarly, for *NBPF12* and *GK2*, not recognized as cancer genes in COSMIC, there were 1 hotspot accumulating 12 mutations in *NBPF12*, and 4 hotspots showing 5 to 6 mutations in *GK2*. In total, 3,860 hotspots were detected in 3,115 genes where 2,639 genes had only 1 hotspot, 378 genes contain 2 hotspots, and 98 genes showed 3 or more hotspots ([Fig. 4](#f0020){ref-type="fig"}A). These hotspots cover 39,815 mutations representing 1.25% of the total mutations and 0.19% of the mutated sites. Common cancer genes showed many hotspots such as *TP53, PIK3CA, APC, PTEN, CDKN2A, ARID1A, FBXW7, NFE2L2*, and 6 or more were estimated in *ERBB2, CTNNB1, BRAF, CIC, KMT2D,* and *DNAH5*. The [Table 1](#t0005){ref-type="table"} shows the 98 genes showing 3 or more hotspots ordered by maximum number of mutations in a hotspot and the number of hotspots. This list is highly enriched in cancer genes, it contains 38% (n = 37, p \< 10^−53^) and 39% (n = 38, p \< 10^−31^) cancer genes from Cosmic [@b0070] and Martincorena [@b0075] respectively. Additionally, this list was compared with other cancer gene lists from Lawrence [@b0205] (n = 34, p \< 10^−43^), High Confidence Drivers (HDC) [@b0210] (n = 37, p \< 10^−38^), and NetSig5000 [@b0215] (n = 3, p \< 10^−3^). Hotspots containing many mutations or hotspots are commonly well-known and present in several cancer gene lists because they have been spotted time ago such as IDH1 in gliomas, BRAF in thyroid, melanoma, and other cancer types. Nevertheless, an analysis of the distribution of mutations show high density corresponding to mutations between 5 and 9 reaching \~70% of detected hotspots ([Fig. 4](#f0020){ref-type="fig"}B). This suggest that many hotspots are needed to be analyzed and experimentally studied.Fig. 3**Examples of hotspots detections.** Three examples of hotspots detections from TCGA data. The figures at left show the mutations along the protein sequence of three genes (EGFR, NBPF12, GK2). Point colors correspond to different cancer types. Symbols correspond to different types of mutations (circles correspond to missense mutations). The histograms at right show the corresponding amino acid positions (vertical, in logarithmic scale) per number of mutations (horizontal). The beta-binomial component is represented in light bar colors and dotted line. The fixed effect is represented by darker bar colors. Significant hotpots are marked. Non-significant fixed effects are also shown. Figures taken from [[http://bioinformatica.mty.itesm.mx/HotSpotsAnnotations]{.ul}](http://bioinformatica.mty.itesm.mx/HotSpotsAnnotations){#ir005} developed in our research group.Fig. 4**Distribution of detected hotspots per gene and mutations.** (A) Hotspots per gene. Vertical axis in logarithm scale. (B) Hotspots per number of mutations.Table 1Genes showing 3 or more recognized hotspots.GeneHotSpotsMutations Min-MaxLists[\*](#tblfn1){ref-type="table-fn"}GeneHotSpotsMutations Min-MaxLists[\*](#tblfn1){ref-type="table-fn"}BRAF611--594CML HZNF44238--11KRAS424--564CML HMDN137--11HPIK3CA229--290CMLNHKIAA202636--11TP536316--251CML HPPM1D36--11CMLNRAS315--203CML HDDX1735--11PTEN1510--112CML HDNAH559--10FBXW799--69CML HCSMD339--10CJAK1314--60CMMECOM39--10C HCTNNB1630--50CML HATRX37--10CM HHRAS47--50CML HC5orf4237--10CDKN2A1210--41CML HUVRAG35--10APC189--40CML HDNAH739--9ERBB269--40CML HTTN78--9PPP2R1A313--33CML HOR51S148--9NFE2L297--32CML HRASA138--9MLNHARID1A99--29CML HSAMD938--9EGFR411--27CML HMGA47--9ML HKMT2D59--26CMADAMTS337--9FGFR238--25CML HALB37--9MSCAF4310--24CHD137--9SF3B147--21C L HZNF1437--9SPOP49--19CML HZNF73237--9MBD6312--17MZNF29246--9KMT2B311--17MADNP36--9LPIK3R1410--17CMLNHTRIM2336--9LMFRP36--17KIF20B47--8HCD93312--16CWF19L237--8TPTE49--16OR2T237--8CHD4311--15CML HUNC7937--8KANSL148--15MFAM193A36--8CTCF311--14CML HZNF50236--8ZBTB7C39--14SLCO1B745--8NF148--13CML HCCDC2737--7PRKDC38--13CFAP6137--7CIC57--13CM HMSH646--7CARHGAP537--13CMVPS13C46--7SMAD237--13CML HBTBD736--7YLPM137--13MTDRD636--7MYOCD310--12LGTF3C435--7THSD7B310--12PTPN1135--7CML HCASP849--12CML HCCDC16846--6ANK339--12LGK236--6CNTNAP239--12CRALGAPA136--6HZFHX439--12CSGALNACT135--6CNOT137--12HPTPN1335--6C HHCN139--11RPS6KA535--6PBRM139--11CML HMAN2A145--5ALG1338--11B3GAT235--5C638--11CLCA435--5[^1]

*TTN* showed 7 'hotspots' but has been marked repeatedly as a 'false positive' gene due to its size (35,991 aa for isoform NP_001254479). Although the distribution of mutations and the fitting for *TTN* seems to correctly detect departures from the expected beta-binomial distribution ([Supplementary Fig. 5A](#s0110){ref-type="sec"}), a possible modeling problem is the intrinsic assumption of homogenous background mutation rates that could be wrong for very long genes. To determine possible modeling failures for *TTN*, the model was fitted by non-overlapping windows of size 1,000 aa along the gene. The results show that the p-value assigned to 5 of the 7 designated 'hotspots' are even more significant by the local fitting ([Supplementary Fig. 5B](#s0110){ref-type="sec"}) suggesting that detections for the whole gene are acceptable. Nevertheless, the estimations of the background mutation along the 35 fitted windows shows systematic increases from 0.68 to 0.80 along the gene ([Supplementary Fig. 5C](#s0110){ref-type="sec"}, probability of mutations = 0) suggesting that most precise estimations could be done by local fitting.

3.5. Variant types and sequence context in hotspots {#s0075}
---------------------------------------------------

Most hotspots methods focus on missense and nonsense mutations, which cover around 75% of all mutations. This has the advantage of focusing on clear biological effects but has the disadvantage of ignoring possible sequence biases that may help to recognize mechanistic effects. In addition, the proposed algorithm is inspired in estimating biases in the distribution of mutations along protein coding regions, which will be affected by selecting types of mutations. Therefore, all small mutations types were used. The disadvantage, however, is that not all variant types may show an interesting biological effect. In addition, it is known that hotspots may be focalized in specific sequence contexts [@b0220]. Accordingly, a comparison of variant types and sequence contexts were performed between hotspots and the overall data in unique positions. To clearly expose the differences, only hotspots carrying 10 or more mutations were compared as shown in [Fig. 5](#f0025){ref-type="fig"} while the complete analysis is shown in [Supplementary Fig. 7](#s0110){ref-type="sec"}. From the input data, the most frequent variant types are *missense, silent,* and *nonsense* accumulating 1.44, 0.564 and 0.116 million mutations. In hotspots, although the most frequent mutations are *missense* (n = 750) surprisingly, *frame shift deletions* counts are very similar (n = 742) even that *frame shift deletions* are more than 20 times less frequent in the overall data. *Frame shift insertions* were also high (n = 327).Fig. 5**Comparison of mutated context sequences in hotspots.** The heatmap at left show the relative percentage of all mutated positions per mutation type and context sequence found in the whole dataset of TCGA data used. Only selected mutations types are shown for clarity (those found in hotspots of 10 or more mutations as shown in middle heatmap). Only distinct mutation sites are considered. Total positions (N) at top, are shown in thousands (k = 1000). The heatmap at the middle shows equivalent percentages found at hotspots positions carrying 10 or more mutations. To facilitate interpretation, the heatmap at the right show the difference of the percentages. The Supplementary Fig. 6 show details of other mutations types and hotspots of 5 to 9 mutations.

The [Fig. 5](#f0025){ref-type="fig"} clearly show that while the sequence context T[C]{.ul}N dominates the overall mutated positions mainly in the T[C]{.ul}T sequence context (where the [C]{.ul} marks the site of mutation), the T[C]{.ul}G is by far the most recurrent context for hotspots while T[C]{.ul}T, T[C]{.ul}A, and T[C]{.ul}C generally decrease. This pattern seems to be clearly present in *missense* and *nonsense* and partially also in *silence* mutations suggesting that there is some type of preference or selection for the T[C]{.ul}G context in these types of variants. Similarly, for hotspots carrying 5 to 9 mutations, the T[C]{.ul}G increase is also observed ([Supplementary Fig. 6](#s0110){ref-type="sec"}). However, in these hotspots, an increase in G[C]{.ul}G, then C[C]{.ul}G and A[C]{.ul}G, were also present suggesting that the overall preference for 5 to 9 mutations seems to be xN[C]{.ul}G. All these results concur with the pattern of mutations from APOBEC [@b0220].

For *frame shift deletions* the observed differences are not so strong, suggesting that, overall, selection pressure is absent or low. The highest increases in differences (+5 relative %) were in A[C]{.ul}C, C[T]{.ul}T, and T[T]{.ul}A. For other types of variants, the changes or the number of occurrences in hotspots are low.

3.6. Hotspots across cancer types {#s0080}
---------------------------------
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3.7. Model parameters correlates with background mutation rates {#s0085}
---------------------------------------------------------------

The estimation of background mutation rates is important for mutation detection methods because it helps to determine deviations [@b0230]. Instead of the expected number of mutations, the fitted *beta-binomial* model can be used to provide estimations of the probability of *k* mutations along chromosomes. By definition, contiguous genes should show similar probabilities even that the fitting was independent. Small deviations of an overall probability should highlight important genes and systematic deviations should show artifactual genes or regions. To validate this, the estimated p-values were compared between genes along chromosomes. The [Fig. 7](#f0035){ref-type="fig"} shows a representative example of the estimations for the chromosome 1 ([Supplementary Fig. 7](#s0110){ref-type="sec"} shows all chromosomes) for the p-value of 0 and 1 mutations (shown in black and red respectively). It is clear that the smoothed mean show some peaks that colocalize with olfactory receptors (vertical gray lines), which has been shown to be highly correlated to late replication timing, low expression, and higher mutation rates [@b0175]. Other gene clusters can be identified, for example, late cornified envelope (LCE) gene cluster in Chr1 ([Fig. 7](#f0035){ref-type="fig"}), regenerating family member (REG) in Chr2, protocadherin beta gene cluster (PCDHB) in Chr5, the histone 1 cluster in Chr6, among others ([Supplementary Fig. 7](#s0110){ref-type="sec"}). Specific deviations such as CDKN2A in Chr9, PTEN in Chr10, TP53 in Chr17 among other are also visible ([Supplementary Fig. 7](#s0110){ref-type="sec"}). These results show that the proposed algorithm provides consistent estimations. Moreover, these estimations are able to capture variations in background mutations rates.Fig. 7**Model estimations along chromosome 1.** The figure shows the density estimations of 0 mutations (dots in black) and 1 mutation (dots in red). The red line in top and black line in bottom show the smoothed estimation (window = 5). The mean value, 0.818 for the former and 0.151 for the last, is shown at right and represented by a horizontal gray line. Vertical gray lines represent genomic positions for annotated olfactory receptors. Some genes farther than 3 standard deviations are annotated. Supplementary Fig. 7 shows equivalent information for all chromosomes. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

4. Discussion {#s0090}
=============

This manuscript shows an algorithm to identify highly recurrent mutations at specific amino acid positions in cancer. The algorithm fits the distribution of amino acid positions along number of mutations using a mixed model that includes a beta-binomial model plus a fixed effect ([Fig. 1](#f0005){ref-type="fig"}). The algorithm proposed made some assumptions and has not been extensively optimized. For example, the termination criteria of nu''mber of iterations and *G* statistic threshold of 1. Nevertheless, the results support an acceptable and competitive performance.

The comparisons of different distributions lead to select the *beta-binomial* model. This makes sense because, in principle, the mutation can be seen as a binomial process during replication and/or repair. Then, instead of fixing *p* along the gene in the binomial process, *p* is random drawn from a *beta* distribution, which absorbs uncertainty due to patient, different positions, and sequence contexts resulting in allowing more uncertainty, covering observed over-dispersion, and fitting the data better. Other statistical models could be tested but the justification, the interpretation, and the adequacy of the model may be difficult.

One of the problems when proposing a predicting or discovery algorithm is how assessing the accuracy. Although other algorithms and models have been proposed, most of them use lists of positive and/or negative curated genes as benchmarking. Instead, simulations were used here showing that, overall, the sensitivity and specificity was \~85%. More importantly, in conditions common for hotspots such as at highest number of mutations, the algorithm shows accuracies around 99%.

Few genes such as TP53, PIK3CA, and PTEN, showed a different tendency in fitting than most genes ([Supplementary Fig. 4](#s0110){ref-type="sec"}). This is presumably due to the high number of hotspots and mutations backed up by the observation that closer genes such as CDKN2A, GATA3, and APC also show high hotspots. This is not a problem because these are well-known cancer genes. Nevertheless, it would be interesting to observe other genes once more mutation data is aggregated in the coming years.

It is assumed that a hotspot have functional impact in cancer [@b0005]. Nevertheless, recent advances have shown that many hotspots arise by artifacts in local sequences such as hairpins susceptible for APOBEC enzymatic activity [@b0220], including the detected gene MB21D2. Therefore, it is difficult to confirm in advance which hotspots will be functional. However, the first step is to detect those that under a certain model seems to be potential hotspots. These hotspots are provided here. Thus, how hotspots must be selected for functional validation? First, those that are well-known cancer genes whose hotspot have not been experimentally tested. Second, the genes showing many hotspots or high number of mutations at the hotspot. These would provide further certainty that any of its hotspots are indeed functional. Nevertheless, in the analysis of cancer data, most genes only show 1 hotspot and most hotspots were found supported by less than 10 mutations ([Fig. 4](#f0020){ref-type="fig"}). Third, check that the gene has not been listed for APOBEC activity [@b0220]. In this context, the database HotSpotsAnnotations has been created ([[http://bioinformatica.mty.itesm.mx:8080/HotSpotsAnnotations]{.ul}](http://bioinformatica.mty.itesm.mx%3a8080/HotSpotsAnnotations){#ir035}) which has been annotated for APOBEC, the ratio of non-synonymous by synonymous mutations, and can be manually annotated by the research community [@b0200]. Fourth, further verification is needed if the gene is super-sized or within artifactual regions such as those around olfactory receptors. Fifth, check the criteria of the ratio of non-synonymous to synonymous mutations [@b0075]. Finally, frame shifts deletions and insertions have not been well studied in the hotspot context and in statistical models. Around one third of the detected hotspots included these mutation types.

The observation that *T[C]{.ul}G* is more prone to form hotspots does not seem to be due to the lack of covariates in the model used. This is based on the fact that sequence context in hotspots were analyzed after normalization by percentage comparing the observed mutational spectra and the hotspots. That is, if all mutational contexts would have similar probability of being established as a hotspot, similar percentages would be observed in hotspots. Instead, more than two-fold was observed in *T[C]{.ul}G* for single nucleotide variants.

Most hotspots carry between 5 and 9 mutations (70%) and also are formed by mutations of different cancer types (91%). Therefore, many hotspots were only detected when mutation from all cancer types were aggregated highlighting the importance of integrating databases. Consequently, as more mutation data is accumulated, more precise detections can be done. One issue is that all datasets must be processed in compatible pipelines, genome annotations, and transcripts to avoid inconsistencies. In this context, other databases such as those from the International Cancer Genome Consortium (ICGC) should improve and confirm the results.

5. Conclusion {#s0095}
=============

Simulations of the proposed algorithm that fit a mixed model of *beta-binomial* plus a fixed effect demonstrated excellent performance for hotspots at highest mutations (around 99% accuracy) and acceptable overall performance (85%). The algorithm was applied to TCGA cancer data detecting more than 3,860 hotspots after FDR correction that account for around 1.25% of the total number of mutations and 0.19% of the mutated amino acid sites.
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Appendix A. Supplementary data {#s0110}
==============================

The following are the Supplementary data to this article:Supplementary figure 1Fitting characteristics in TCGA data. The figure shows the distribution of the fitted fixed effect F (horizontal) relative to the total number of mutations (vertical). A value of 1 represent 100% of the mutations. It is clear that most fittings absorb 100% of mutations (highest vertical bar at top). Nevertheless, few fittings are fractions of the total number of mutations, mainly at low number of mutations (5 or lower). Therefore, these fittings capture biases in the distribution relative to the beta-binomial model.

Supplementary figure 2Comparisons of best fitting among four distributions. Panel A shows a comparison of the best distribution for different sets of genes. Panel B compares the best two distributions. Panel C shows results if one distribution is not considered.

Supplementary figure 3Fitting the algorithm proposed. (A) Differences in the α parameter. Two tendencies are observed, one showing low differences (\< 0 in logarithm 10 scale) and other around 10^3^. (B) Differences in β parameter.

Supplementary figure 4FDR estimation for amino acid positions carrying 4 or more mutations. Two tendencies are observed, a major below \~20 mutations and a minor above \~20. The last includes TP53, PIK3CA, and PTEN hotspots mainly as labelled. The vertical *nMut* was jittered for clarity in density estimation. FDR q-value was limited to 10^−10^ (at left) for clarity.

Supplementary figure 5Analysis of the titin (TTN) gene fitting. (A) Mutations along the protein. The distribution is shown at the right. Raw α and β parameters refer to the overall fitting before the proposed algorithm. Fitted+Fixed refer to α and β parameters obtained after running the proposed algorithm. (B) 'Hotspots' mutations for 8 and 9 mutations. The 'whole gene' p-value was obtained fitting all mutations in one run while window p-values are the resulted p-values after fitting mutations in non-overlapping windows of 1,000 amino acids. Five of the seven 'hotspots' marked in bold are more significant in the local windowed estimations than in the global gene estimation. The window number (w) is shown enclosed in parenthesis along with local α and β fitted values. (C) Effect of the local fitting along windows into the probability of mutations.

Supplementary figure 6Comparison of mutated context sequences in hotspots. The first two heatmaps show the relative percentage of mutated positions per mutation type found in the whole dataset of TCGA data used. The first show the types of mutations not found in hotspots of 10 mutations or more. The second show the types of mutations found in hotspots of 10 or more mutations. Only distinct sites are considered. Total positions (N), are shown in thousands (k=1000). The third heatmap shows equivalent percentages found at hotspots positions carrying 10 or more mutations. The last heatmap at right show equivalent percentages for hotspots carrying 5 to 9 mutations.

Supplementary figure 7Model estimations along chromosomes. Each panel shows the density estimations of 0 mutations (dots in black) and 1 mutation (dots in red) for a chromosome (as labeled at right). The red line in top and black line in bottom show the smoothed estimation (window=5). The mean value is shown at right and represented by a horizontal gray line. Vertical gray lines represent genomic positions for annotated olfactory receptors. Some genes farther than 3 standard deviations are annotated.

Supplementary table 1Number of samples mutations per cancer type used in this study.

Supplementary table 2Genes strictly cancer type-specific.

Supplementary table 3Genes enriched by cancer type-specific.
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